Plakoglobin is differentially expressed in alveolar and embryonal rhabdomyosarcoma and is regulated by DNA methylation and histone acetylation

Carcinogenesis

Volumn 27, Issue 9, 2006, Pages 1758-1767

  Gastaldi, Tamara ^b   Bonvini, Paolo ^b   Sartori, Francesca ^b   Marrone, Agnese ^a   Iolascon, Achille ^a   Rosolen, Angelo ^b  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; HISTONE; HISTONE H4; PLAKOGLOBIN; TRICHOSTATIN A;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CARCINOGENESIS; CELL NUCLEUS; CONTROLLED STUDY; CPG ISLAND; CYTOPLASM; DEACETYLATION; DNA METHYLATION; EMBRYONAL RHABDOMYOSARCOMA; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; TRANSCRIPTION INITIATION SITE;

ACETYLATION; CELL NUCLEUS; CELL PROLIFERATION; CYTOPLASM; CYTOSKELETON; DNA METHYLATION; GAMMA CATENIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONES; HYDROXAMIC ACIDS; PROMOTER REGIONS (GENETICS); RHABDOMYOSARCOMA, ALVEOLAR; RHABDOMYOSARCOMA, EMBRYONAL;

EID: 33748148713     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgl008     Document Type: Article

References (48)

1. Wexler,L.H. and Helman,L.J. (1997) Rhabdomyosarcoma and the undifferentiated sarcoma. In: Pizzo,P.A. and Poplack,P.G., (eds) Principles and Practice of Pediatric Oncology. Raven-Lippincott, Philadelphia, pp. 799-829.
2. Newton, W.A.J., Gehan,E.A., Webber,B.L. et al. (1995) Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification - an Intergroup Rhabdomyosarcoma Study. Cancer, 76, 1073-1085.
3. Barr,F.G. (1997) Molecular genetics and pathogenesis of rhabdomyosarcoma. J. Pediatr. Hematol. Oncol., 19, 483-491.
4. Davis,R.J., D'Cruz,C.M., Lovell,M.A., Biegel,J.A. and Barr,F.G. (1994) Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma. Cancer Res., 54, 2869-2872.
5. Fredericks,W.J., Galili,N., Mukhopadhyay,S., Rovera,G., Bennicelli,J., Barr,F.G. and Rauscher,F.J.,III (1995) The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3. Mol. Cell. Biol., 15, 1522-1535.
6. Bennicelli,J.L., Edwards,R.H. and Barr,F.G. (1996) Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma. Proc. Natl Acad. Sci. USA, 93, 5455-5459.
7. Ginsberg,J.P., Davis,R.J., Bennicelli,J.L., Nauta,L.E. and Barr,F.G. (1998) Up-regulation of MET but not neural cell adhesion molecule expression by the PAX3-FKHR fusion protein in alveolar rhabdomyosarcoma. Cancer Res., 58, 3542-3546.
8. Ferracini,R., Olivero,M., Di Renzo,M.F., Martano,M., De Giovanni,C., Nanni,P., Basso,G., Scotlandi,K., Lollini,P.L. and Comoglio,P.M. (1996) Retrogenic expression of the MET proto-oncogene correlates with the invasive phenotype of human rhabdomyosarcomas. Oncogene, 12, 1697-1705.
9. Ricci,C., Landuzzi,L., Rossi,L. et al. (2000) Expression of HER/erbB family of receptor tyrosine kinases and induction of differentiation by glial growth factor 2 in human rhabdomyosarcoma cells. Int. J. Cancer, 87, 29-36.
10. Morin,P.J. (1999) Beta-catenin signaling and cancer. Bioessays, 21, 1021-1030.
11. Papkoff,J. (1997) Regulation of complexed and free catenin pools by distinct mechanisms - Differential effects of Wnt-1 and v-Src. J. Biol. Chem., 272, 4536-4543.
12. BenZeev,A. and Geiger,B. (1998) Differential molecular interactions of beta-catenin and plakoglobin in adhesion, signaling and cancer. Curr. Opin. Cell Biol., 10, 629-639.
13. Polakis,P. (1999) The oncogenic activation of beta-catenin. Curr. Opin. Genet. Dev., 9, 15-21.
14. Polakis,P. (2000) Wnt signaling and cancer. Genes Dev., 14, 1837-1851.
15. Sadot,E., Simcha,I., Iwai,K., Ciechanover,A., Geiger,B. and BenZe'ev,A. (2000) Differential interaction of plakoglobin and beta-catenin with the ubiquitin-proteasome system. Oncogene, 19, 1992-2001.
16. Aberle,H., Bierkamp,C., Torchard,D. et al. (1995) The human plakoglobin gene localizes on chromosome 17q21 and is subjected to loss of heterozygosity in breast and ovarian cancers. Proc. Natl Acad. Sci. USA, 92, 6384-6388.
17. Simcha,I., Geiger,B., YehudaLevenberg,S., Salomon,D. and BenZeev,A. (1996) Suppression of tumorigenicity by plakoglobin: An augmenting effect of N-cadherin. J. Cell Biol., 133, 199-209.
18. Harada,K., Toyooka,S., Maitra,A. et al. (2002) Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene, 21, 4345-4349.
19. Rathi,A., Virmani,A.K., Harada,K., Timmons,C.F., Miyajima,K., Hay,R.J., Mastrangelo,D., Maitra,A., Tomlinson,G.E. and Gazdar,A.F. (2003) Aberrant methylation of the HIC1 promoter is a frequent event in specific pediatric neoplasms. Cli. Cancer Res., 9, 3674-3678.
20. Litt,M.D., Simpson,M., Gaszner,M., Allis,C.D. and Felsenfeld,G. (2001) Correlation between histone lysine methylation and developmental changes at the chicken beta-globin locus. Science, 293, 2453-2455.
21. Nakayama,J., Rice,J.C., Strahl,B.D., Allis,C.D. and Grewal,S.I. (2001) Role of histone H3 lysine 9 methylation in epigenetic control of heterochromatin assembly. Science, 292, 110-113.
22. Tazi,J. and Bird,A. (1990) Alternative chromatin structure at CpG islands. Cell, 60, 909-920.
23. Strahl,B.D., Ohba,R., Cook,R.G. and Allis,C.D. (1999) Methylation of histone H3 at lysine 4 is highly conserved and correlates with transcriptionally active nuclei in Tetrahymena. Proc. Natl Acad. Sci. USA, 96, 14967-14972.
24. Nan,X., Ng,H.H., Johnson,C.A., Laherty,C.D., Turner,B.M., Eisenman,R.N. and Bird,A. (1998) Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature, 393, 386-389.
25. Jones,P.L., Veenstra,G.J., Wade,P.A., Vermaak,D., Kass,S.U., Landsberger,N., Strouboulis,J. and Wolffe,A.P. (1998) Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet., 19, 187-191.
26. Rosette,C. and Karin,M. (1995) Cytoskeletal control of gene expression: depolymerization of microtubules activates NFκB. J. Cell. Biol., 128, 1111-1119.
27. Herman,J.G., Graff,J.R., Myohanen,S., Nelkin,B.D. and Baylin,S.B. (1996) Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA., 93, 9821-9826.
28. Potter,E., Braun,S., Lehmann,U. and Brabant,G. (2001) Molecular cloning of a functional promoter of the human plakoglobin gene. Eur. J. Endocrinol., 145, 625-633.
29. Amitay,R., Nass,D., Meitar,D., Goldberg,I., Davidson,B., Trakhtenbrot,L., Brok Simoni,F., Ben Ze'ev,A., Rechavi,G. and Kaufmann,Y. (2001) Reduced expression of plakoglobin correlates with adverse outcome in patients with neuroblastoma. Am. J. Path., 159, 43-49.
30. Santi,D.V., Norment,A. and Garrett,C.E. (1984) Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc. Natl Acad. Sci. USA., 81, 6993-6997.
31. Walia,H., Chen,H.Y., Sun,J.M., Holth,L.T. and Davie,J.R. (1998) Histone acetylation is required to maintain the unfolded nucleosome structure associated with transcribing DNA. J. Biol. Chem., 273, 14516-14522.
32. Shim,J.S., Kim,D.H. and Kwon,H.J. (2004) Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells. Oncogene, 23, 1704-11.
33. Winn,R.A., Bremnes,R.M., Bemis,L., Franklin,W.A., Miller,Y.E., Cool,C. and Heasley,L.E. (2002) Gamma-catenin expression is reduced or absent in a subset of human lung cancers and re-expression inhibits transformed cell growth. Oncogene, 21, 7497-7506.
34. Cerrato,A., Fulciniti,F., Avallone,A., Benincasa,G., Palombini,L. and Grieco,M. (1998) Beta- and gamma-catenin expression in thyroid carcinomas. J. Pathol., 185, 267-272.
35. Pirinen,R.T., Hirvikoski,P., Johansson,R.T., Hollmen,S. and Kosma,V.M. (2001) Reduced expression of alpha-catenin, beta-catenin, and gamma-catenin is associated with high cell proliferative activity and poor differentiation in non-small cell lung cancer. J. Clin. Pathol., 54, 391-395.
36. Syrigos,K.N., Harrington,K., Waxman,J., Krausz,T. and Pignatelli,M. (1998) Altered gamma-catenin expression correlates with poor survival in patients with bladder cancer. J. Urol., 160, 1889-1893.
37. Buchner,A., Oberneder,R., Riesenberg,R., Keiditsch,E. and Hofstetter,A. (1998) Expression of plakoglobin in renal cell carcinoma. Anticancer Res., 18, 4231-4235.
38. Pantel,K., Passlick,B., Vogt,J., Stosiek,P., Angstwurm,M., SeenHibler,R., Haussinger,K., Thetter,O., Izbicki,J.R. and Riethmuller,G. (1998) Reduced expression of plakoglobin indicates an unfavorable prognosis in subsets of patients with non-small-cell lung cancer. J. Clin. Oncol., 16, 1407-1413.
39. Breault,J.E., Shiina,H., Igawa,M. et al. (2005) Methylation of the gamma-catenin gene is associated with poor prognosis of renal cell carcinoma. Clin. Cancer Res., 11, 557-564.
40. He,T.C., Sparks,A.B., Rago,C., Hermeking,H., Zawel,L., DaCosta,L.T., Morin,P.J., Vogelstein,B. and Kinzler,K.W. (1998) Identification of c-MYC as a target of the APC pathway. Science, 281, 1509-1512.
41. Shtutman,M., Zhurinsky,J., Simcha,I., Albanese,C., D'Amico,M., Pestell,R. and Ben Ze'ev,A. (1999) The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc. Natl Acad. Sci. USA, 96, 5522-5527.
42. Charrasse,S., Comunale,F., Gilbert,E., Delattre,O. and Gauthier-Rouviere,C. (2004) Variation in cadherins and catenins expression is linked to both proliferation and transformation of rhabdomyosarcoma. Oncogene, 23, 2420-30.
43. Jankowski,K., Kucia,M., Wysoczynski,M. et al. (2003) Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res., 63, 7926-7935.
44. Kondo, Y., Shen,L. and Issa,J.P. (2003) Critical role of histone methylation in tumor suppressor gene silencing in colorectal cancer. Mol. Cell. Biol., 23, 206-215.
45. Cameron,E.E., Bachman,K.E., Myohanen,S., Herman,J.G. and Baylin,S.B. (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet., 21, 103-107.
46. Eden,S., Hashimshony,T., Keshet,I., Cedar,H. and Thorne,A.W. (1998) DNA methylation models histone acetylation. Nature, 394, 842.
47. Kutko,M.C., Glick,R.D., Butler,L.M., Coffey,D.C., Rifkind,R.A., Marks,P.A., Richon,V.M. and LaQuaglia,M.P. (2003) Histone deacetylase inhibitors induce growth suppression and cell death in human rhabdomyosarcoma in vitro. Clin. Cancer Res., 9, 5749-5755.
48. Jaboin,J., Wild,J., Hamidi,H., Khanna,C., Kim,C.J., Robey,R., Bates,S.E. and Thiele,C.J. (2002) MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res., 62, 6108-6115.